Updated: Sep 7
On July 19, I had the honor of speaking in the 6th-anniversary commemorative symposium of the Japan Medical Venture Association. During the symposium, it was highlighted that Japanese government is actively supporting in the healthcare field in various ways. As part of this support, MHLW has issued a guidance concerning “two-step approval” to expedite the market entry of SaMD including AI SaMD.
It was a promising occasion, and I wanted to share this exciting development with you. This advancement in Japan's support for innovative medical ventures, especially in the SaMD presents new opportunities for us in the Japanese market.
Should you have any questions or require further information, please do not hesitate to reach out to us. We are committed to leveraging this opportunity to deliver enhanced value to your business.